Voyager Therapeutics (FRA:VT6) 6-Month Price Index: 0.85 (As of Aug. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:VT6 Voyager Therapeutics Inc FRA:VT6
52 GF Score
Price €2.90
GF Value €1.38
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Voyager Therapeutics 6-Month Price Index?

Voyager Therapeutics FRA:VT6 +2.18% 52 6-Month Price Index is 0.85 as of Aug. 30, 2026. GuruFocus rates FRA:VT6 with a GF Score™ of 52/100 and a GF Value™ of €1.38 (Significantly Overvalued). The stock has 6 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-08-30), Voyager Therapeutics's 6-Month Price Index is 0.85.

Voyager Therapeutics  (FRA:VT6) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Voyager Therapeutics 6-Month Price Index Related Terms

FRA:VT6 vs NERV, DTIL, GLSI: 6-Month Price Index Comparison

For the Biotechnology subindustry, Voyager Therapeutics's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

FRA:VT6
52GF Score
Voyager Therapeutics Inc FRA:VT6
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyager Therapeutics  (FRA:VT6) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.85 mean?
Voyager Therapeutics (FRA:VT6) has a 6-Month Price Index of 0.85 as of Aug. 30, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Voyager Therapeutics and its competitors.
Is Voyager Therapeutics' 6-Month Price Index too high?
Voyager Therapeutics' current 6-Month Price Index is 0.85. Overall, Voyager Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Voyager Therapeutics' 6-Month Price Index compare to NERV and DTIL?
Voyager Therapeutics' 6-Month Price Index of 0.85 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Biotechnology company?
A good 6-Month Price Index depends on the Biotechnology industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Voyager Therapeutics and its competitors. Voyager Therapeutics's current 6-Month Price Index is 0.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyager Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Voyager Therapeutics (FRA:VT6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.38, compared to a current price of €2.90 — trading 110.1% above its estimated fair value. The current 6-Month Price Index is 0.85. Voyager Therapeutics' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Voyager Therapeutics (FRA:VT6), the current 6-Month Price Index is 0.85 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Voyager Therapeutics (FRA:VT6) Overvalued in 2026?

Based on GuruFocus' analysis, Voyager Therapeutics stock appears to be overvalued. The current stock price of €2.90 is trading 110.1% above its estimated GF Value™ of €1.38. GuruFocus considers Voyager Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:VT6:

  • 6-Month Price Index: 0.85
  • GF Value™: €1.38 vs. price of €2.90 (110.1% above fair value)
  • GF Score™: 52/100 with 6 warning signs

No single metric tells the full story. See the FRA:VT6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Voyager Therapeutics Business Description

Other Exchanges VYGR:USAVYGR:Mexico
Address 75 Hayden Avenue, Lexington, MA, USA, 02421
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
52GF Score

Get the complete analysis for FRA:VT6

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.90
Price
€1.38
GF Value